Clinical Research Directory

Inclusion Criteria: * Age 18-75 years at the time of inclusion * Written informed consent * Patients with relapsed/refractory CD19 positive B-cell lymphomas, who have received at least two lines of treatment * With measurable disease * ECOG PS 0-2 at protocol entry * Estimated life expectancy of 3 months or longer * Hemoglobin ≥ 8 g/dL (≥5 mmol/l); Platelets ≥ 75 x 10E9/L; Absolute neutrophil count ≥ 1.0 x 10E9/L; Platelets ≥ 50 x 10E9/L permitted if documented bone marrow involvement; Serum bilirubin ≤ 1.5 x upper limit of normal (ULN), or ≤3 x ULN if elevation is due to hepatic involvement by lymphoma; Serum glutamic-oxaloacetic transaminase (AST) and/or serum glutamic-pyruvic transaminase (ALT) ≤ 2.5 x ULN, or ≤ 5 x ULN if elevation is due to hepatic involvement by lymphoma; Serum creatinine ≤ 1.5 x ULNb; left ventricular ejection fraction (LVEF) ≥ 50% * Women of childbearing potential must use safe anticonception (e.g. contraceptive pills, intrauterine devices etc.) during the study and 6 months after the administration of study drug; Male patients must use contraception for the duration of the study and 6 months after the administration of study drug if his partner is of childbearing potential Exclusion Criteria: * Patients with heart disease: atrial fibrillation; History of Class III or IV New York Heart Association (NYHA) heart failure, myocardial infarction or other significant cardiac disease within 12 months of screening; LVEF\<50%; clinical significant pericardial effusion; Long QT syndrome * History of severe pulmonary function impairment * With other uncontrolled malignancy * With active bacterial, viral, or fungal infections * WIth uncontrolled autoimmune disease or congential immunodeficiency * HIV antibody positive patients * Known severe hypersensitivity to biological product * Patients with known active central nervous system (CNS) disease, including lymphoma CNS involvement * Patients with prior CAR-T therapy * History of allogeneic stem cell transplantation * History of autogeneic stem cell transplantation within 6 months of screening * History of major surgery within 4 weeks of screening * Patients receiving live (attenuated) vaccines within 6 weeks of screening * Pregnant or lactating women, or pregnant plan within 12 months * Involvement of cardiac tissue by lymphoma * with emergency due to oncothlipsis * Unwillingness or inability to comply with the protocol * Deemed 'unfit' by the treating physician